Commentary: the PROactive study--the glass is half full.
Fonseca
Vivian
V
Tulane University Medical Center, New Orleans, Louisiana 70112, USA. vfonseca@tulane.edu
Jawa
Ali
A
Asnani
Sunil
S
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D048909:Diabetes Complications / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000517:prevention & control; D018450:Disease Progression; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology*; D007333:Insulin Resistance; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control; D000077205:Pioglitazone; D020521:Stroke / Q000401:mortality / Q000517:prevention & control; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone